Depressive Disorders Therapeutics
1. Cymbalta patent expiration
Treatment: Management of fibromyalgia (fm); Method of treating anxiety
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(5 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(11 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(6 years ago) | |
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(12 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(12 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-617) | Nov 19, 2012 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | Apr 18, 2016 |
| M(M-61) | Oct 18, 2015 |
| New Patient Population(NPP) | Apr 20, 2023 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Dosage: CAPSULE, DELAYED REL PELLETS
How can I launch a generic of CYMBALTA before it's drug patent expiration?
More Information on Dosage
CYMBALTA family patents
2. Exxua patent expiration
Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7538116 | FABRE KRAMER | Treatment of sexual disorders |
Sep, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2028 |
Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient
NCE-1 date: 23 September, 2027
Market Authorisation Date: 22 September, 2023
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
EXXUA family patents